8th MASH Drug Development Summit
When:
Tuesday, Sep 24, 2024 8:00a -
Thursday, Sep 26, 2024 4:15p
Tuesday, Sep 24, 2024 8:00a -
Thursday, Sep 26, 2024 4:15p
Where:
Hilton Boston Logan Airport
One Hotel Drive
Boston, Massachusetts 02128
Admission:
$2999.00 - $5097.00
Hosted by:
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/2611979-0?pid=5248
Madrigal's blockbuster drug gaining FDA approval this March has opened the doors to a wave of therapeutics from Eli Lilly, Boehringer Ingelheim, AstraZeneca, Amgen, Akero Therapeutics and more that hold huge promise in Phase 1, 2, and 3 clinical trials. Paired with the boom of GLP-1s, these milestones have reinvigorated investment throughout the metabolic space.
The 8th MASH Drug Development Summit is the perfect forum to unite and discuss the evolving drug development opportunity for MASH and metabolic diseases. From optimizing clinical trial design to overcoming regulatory challenges, combatting fibrosis, navigating GLP-1 usage, optimizing RWE integration and achieving accurate non-invasive biomarkers, you won't find this industry-led insight anywhere else.
Join 120+ C-Level cardiometabolic stakeholders and thought leaders to make key connections, gain competitive insights and hear the latest data to shape the future of your MASH development pipeline.
URLs:
Tickets: https://go.evvnt.com/2611979-2?pid=5248
Brochure: https://go.evvnt.com/2611979-3?pid=5248
Prices:
Industry Pricing - Conference Only: USD 2999.00,
Industry Pricing - Conference + Clinical Workshop Day: USD 4197.00,
Industry Pricing - Conference + Pre-Clinical Workshop Day: USD 4197.00,
Vendor Pricing - Conference Only: USD 3699.00,
Vendor Pricing - Conference + Clinical Workshop Day: USD 5097.00,
Vendor Pricing - Conference + Pre-Clinical Workshop Day: USD 5097.00
Speakers: Adam Bell, Vice President, Neuraly, Bonnie Fendrock, Chief Executive Officer and Co-founder, Cyta Therapeutics, Charlotte Scott, Professor, Ghent University, Cynthia Arbeeny, CSO, Mitotherapeutix, David Brenner, Chief Executive Officer, Sanford Burnham Prebys, David Lloyd, Vice President, Insitro, Ezra Lowe, Vice President, Galectin Therapeutics, François Briand, Director - Research and Business Development, Physiogenex, Gerald Horan, Senior Scientific Director, Bristol Myers Squibb, Hank Mansbach, Chief Medical Officer, 89 Bio, Jay Kim, Chief Executive Officer, Therasid Bio, Jeff McIntyre. President, Global Liver Institute, Jerry Colca, Chief Scientific Officer, Cirius, Jingyu (Julia) Luan, Senior Director, AstraZeneca, Kai-Min Chu, Chief Executive Officer, Sinew, Katarina Wikstrom, Global VP Product Development, Almac, Kathleen Elias, Co-founder; Vice President - Research and Translational Medicine, Seal Rock Therapeutics, Kristin Fiorino, Medical Director, AstraZeneca, Lichuan Yang, Senior Director - Disease Model Development and Biomarkers, KBI, Manu Chakravarthy, SVP and Global Head of Cardiovascular, Renal and Metabolism Product Development, Carmot, Maria Trujillo, Senior Principal Scientist, Merck, Matt Bryant, Vice President, Boston Pharmaceuticals, Meena Bansal, Professor of Medicine, Mount Sinai, Michael Cooreman, Chief Medical Officer, Inventiva, Miriam Kidron, Chief Scientific Officer, Oramed, Oliver Yoa-Pu Hu, Professor, Taiwan University, Pitchumani Sivakumar, Director Translational Medicine, Pfizer, Rebecca Taub, Chief Medical Officer, Madrigal, Reshma Shringarpure, Vice President, Akero, Rosemarie Sellati, Director, Regeneron, Sarah Wills, Director, AstraZeneca, Scott Harris, Chief Medical Officer, Altimmune, Sherrie Pietranico Cole, Senior Director, Regeneron, Sophie Jeannin, Chief Medical Officer, Summit Clinical Research, Stephanie Watkins, Senior Director, Gilead, Tatiana Kisseleva, Associate Professor, University of California, Thomas Fabre, Senior Principal Scientist - Fibrosis, Pfizer, Yao-Yao Zhu, Director, Global Regulatory Affairs, AstraZeneca
